{"id":"placebo-to-gsk3196165-sarilumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (including serious infections)"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Hyperlipidemia"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sarilumab binds to and inhibits the IL-6 receptor on immune cells and other tissues, preventing IL-6-mediated inflammation. This mechanism suppresses the production of inflammatory cytokines and reduces systemic inflammation, making it effective in conditions driven by IL-6 overproduction such as rheumatoid arthritis and potentially other inflammatory disorders.","oneSentence":"Sarilumab is a monoclonal antibody that blocks the interleukin-6 receptor (IL-6R), reducing inflammatory signaling in immune-mediated diseases.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:28:46.294Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis (moderate to severe)"},{"name":"COVID-19 (severe pneumonia)"}]},"trialDetails":[{"nctId":"NCT04134728","phase":"PHASE3","title":"Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-10-31","conditions":"Arthritis, Rheumatoid","enrollment":550}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to GSK3196165/ Sarilumab","genericName":"Placebo to GSK3196165/ Sarilumab","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sarilumab is a monoclonal antibody that blocks the interleukin-6 receptor (IL-6R), reducing inflammatory signaling in immune-mediated diseases. Used for Rheumatoid arthritis (moderate to severe), COVID-19 (severe pneumonia).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}